ICVX(Delisted)
Icosavax·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ICVX
Icosavax, Inc.
A biopharmaceutical company that develops vaccines against infectious diseases
1930 Boren Avenue, Suite 1000, Seattle, Washington 98101
--
Icosavax, Inc., was incorporated in Delaware on November 1, 2017. The company is a biopharmaceutical company that develops vaccines against infectious diseases using innovative virus-like particle (VLP) platform technology, with an initial focus on life-threatening respiratory diseases. The company's VLP platform technology is designed to enable multivalent, particle-based displays of complex viral antigens, which the company believes will induce broad, strong and long-lasting protection against specific target viruses. The company's products include vaccine candidates for some of the most common viral causes of pneumonia. The company is developing these drug candidates for the elderly, a patient population with high unmet need. The company's lead vaccine candidate, IVX-A12, is a bivalent vaccine candidate, or a mixture of two different VLP vaccine candidates.
Company Financials
EPS
ICVX has released its 2023 Q3 earnings. EPS was reported at -0.44, versus the expected -0.57, beating expectations. The chart below visualizes how ICVX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
